Silk Road Medical, Inc (NASDAQ:SILK) Stock Holdings Increased by Renaissance Technologies LLC

Renaissance Technologies LLC raised its holdings in shares of Silk Road Medical, Inc (NASDAQ:SILK) by 14.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 485,500 shares of the company’s stock after buying an additional 60,900 shares during the period. Renaissance Technologies LLC owned about 1.23% of Silk Road Medical worth $13,128,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in SILK. State Board of Administration of Florida Retirement System lifted its position in shares of Silk Road Medical by 9.9% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 12,065 shares of the company’s stock valued at $221,000 after acquiring an additional 1,090 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Silk Road Medical by 4.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 34,905 shares of the company’s stock valued at $640,000 after purchasing an additional 1,490 shares during the period. PNC Financial Services Group Inc. increased its stake in Silk Road Medical by 1,293.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,523 shares of the company’s stock worth $31,000 after purchasing an additional 2,342 shares in the last quarter. Quest Partners LLC acquired a new stake in Silk Road Medical during the 4th quarter worth about $62,000. Finally, Bellevue Group AG lifted its stake in Silk Road Medical by 0.4% during the fourth quarter. Bellevue Group AG now owns 1,435,682 shares of the company’s stock valued at $17,616,000 after buying an additional 5,120 shares in the last quarter.

Insider Transactions at Silk Road Medical

In related news, EVP Kevin M. Klemz sold 2,268 shares of Silk Road Medical stock in a transaction on Monday, August 19th. The shares were sold at an average price of $27.10, for a total value of $61,462.80. Following the completion of the sale, the executive vice president now owns 162,926 shares of the company’s stock, valued at approximately $4,415,294.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.90% of the stock is currently owned by company insiders.

Silk Road Medical Trading Down 0.0 %

NASDAQ SILK opened at $27.49 on Monday. The company has a market capitalization of $1.12 billion, a PE ratio of -20.07 and a beta of 1.53. Silk Road Medical, Inc has a 1-year low of $6.08 and a 1-year high of $27.51. The company has a current ratio of 7.63, a quick ratio of 6.69 and a debt-to-equity ratio of 0.49. The firm’s fifty day simple moving average is $27.14 and its 200-day simple moving average is $23.12.

Silk Road Medical (NASDAQ:SILK) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.04). Silk Road Medical had a negative net margin of 29.53% and a negative return on equity of 37.30%. The firm had revenue of $51.20 million for the quarter, compared to analyst estimates of $49.74 million. During the same quarter in the prior year, the firm earned ($0.35) earnings per share. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Silk Road Medical, Inc will post -1.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on SILK shares. Lake Street Capital restated a “hold” rating and set a $27.50 price target (down previously from $28.00) on shares of Silk Road Medical in a report on Tuesday, June 18th. Argus cut Silk Road Medical from a “buy” rating to a “sell” rating in a research report on Thursday, July 11th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $27.50 price target (up from $23.00) on shares of Silk Road Medical in a research report on Wednesday, July 17th. Two investment analysts have rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $20.29.

Silk Road Medical Profile

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.